SAVA Raises £7.4M in Seed Investment to Redefine Health Monitoring

Over seven and a half million euros have been raised by the London-based SAVA in order to construct preventative, individualized, and precise health monitoring at scale. With the announcement that it has raised over £7.4 million in a Seed investment round led by Balderton Capital and Exor Ventures, SAVA, the firm that is redefining health monitoring with its real-time, inexpensive, and painless microsensor, is emerging from five years of stealth technology today.

An innovative and ground-breaking microsensing device has been developed by SAVA, which was established by Renato Circi and Rafael Michali, both of whom are bioengineers from Imperial College London. This device is able to detect molecules in the interstitial fluid, which is located just under the skin. The intelligent and connected wearable patch that it offers has been developed to facilitate the streamlining of this data and to provide it directly to the user's phone.

The first microsensor developed by SAVA is geared toward monitoring glucose levels in diabetic patients. Diabetes is expected to affect roughly 783 million persons by the year 2045, which is approximately one in every eight adults. For the purpose of effectively managing their disease, individuals who have diabetes rely on glucose monitoring systems that are accurate.

Sava has just received authorization from the Medicines and Healthcare Products Regulatory Agency (MHRA) in the United Kingdom to proceed with clinical trials on individuals who have diabetes. These trials will assist Sava in validating its innovative technology on a more extensive scale.